drugset / Trial / NCT00300521

Liver Transplantation With ADV-TK Gene Therapy Improves Survival in Patients With Advanced Hepatocellular Carcinoma

NCT00300521

RandomizedParallel-groupOpen-labelTreatment

Summary

Previous rather poor results in liver transplantation (LT) of patients with advanced hepatocellular carcinoma (HCC) have made the application of LT very limited in treatment of HCC. The advantages of ADV-TK gene therapy highlight its potentiality as adjuvant treatment for HCC patients after LT. We reported here the improved outcome of LT with combined treatment of ADV-TK gene therapy in patients with intermediate or advanced HCC.

Timeline

Start
2000-09
Primary completion
Completion
2005-11

Drugs

EvaluationDrugModalityDoseRoute
Subject aglatimagene besadenovec Unknown